Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.

ABSTRACT:

Background

T-cell immunoglobulin and mucin domain 3 (TIM-3) is known as a negative immune regulator and emerging data have implicated TIM-3 a pivotal role in suppressing antitumor immunity. The co-stimulatory receptor CD137 is transiently upregulated on T-cells following activation and increases their proliferation and survival when engaged. Although antagonistic anti-TIM-3 or agonistic anti-CD137 antibodies can promote the rejection of several murine tumors, some poorly immunogenic tumors were refractory to this treatment. In this study, we sought to evaluate whether combined TIM-3 blockade and CD137 activation would significantly improve the immunotherapy in the murine ID8 ovarian cancer model.

Methods

Mice with established ID8 tumor were intraperitoneally injected with si

SUBMITTER: Guo Z 

PROVIDER: S-EPMC3853027 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature